CRISPR Therapeutics AG (CRSP) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to ...

To the research team working to save him, KJ Muldoon was first known only as Patient Eta. But within months, KJ’s name — and ...

This year, gene-editing technology was customized to fix mutations in a single patient’s genes for the first time.

To compete at iGEM, a sort of science Olympics, teens at a Georgia high school set their sights on finding a better way to ...

If you have been wondering whether CRISPR Therapeutics at around $57 a share is a bargain or a bubble, you are not alone. This stock sits at the crossroads of high science and high expectations. The ...

A groundbreaking new treatment using genome-edited immune cells, developed by scientists at UCL (University College London) ...

Casgevy, now a "national priority" drug, helped kids with sickle cell and thalassemia, results which may help toward a label ...

Syntax Bio, a synthetic biology company programming the next generation of cell therapies, today announced the publication of ...

Discover why Crispr Therapeutics AG is a strong buy with FDA-approved Casgevy, a promising pipeline, and major growth ...

Despite a challenging CASGEVY launch, high cash burn, and an almost 10% YTD share count growth, CRISPR’s pipeline breadth and ...

For years, Yale researchers David Breslow and Mustafa Khokha have worked together with a similar challenge in their ...

CRISPR, the gene-editing technology which won its creators the 2020 Nobel Prize for Chemistry, is most well-known for its ...